493 related articles for article (PubMed ID: 25964209)
1. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
2. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
3. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
4. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.
Morad SA; Levin JC; Shanmugavelandy SS; Kester M; Fabrias G; Bedia C; Cabot MC
Mol Cancer Ther; 2012 Nov; 11(11):2352-61. PubMed ID: 22962326
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.
Ponnusamy S; Meyers-Needham M; Senkal CE; Saddoughi SA; Sentelle D; Selvam SP; Salas A; Ogretmen B
Future Oncol; 2010 Oct; 6(10):1603-24. PubMed ID: 21062159
[TBL] [Abstract][Full Text] [Related]
6. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
7. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.
Huwiler A; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2007 Aug; 63(2):150-9. PubMed ID: 17560117
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
[TBL] [Abstract][Full Text] [Related]
9. Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines.
Vethakanraj HS; Babu TA; Sudarsanan GB; Duraisamy PK; Ashok Kumar S
Biochem Biophys Res Commun; 2015 Aug; 464(3):833-9. PubMed ID: 26188095
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis.
White-Gilbertson S; Lu P; Jones CM; Chiodini S; Hurley D; Das A; Delaney JR; Norris JS; Voelkel-Johnson C
Cancer Med; 2020 May; 9(9):3142-3152. PubMed ID: 32135040
[TBL] [Abstract][Full Text] [Related]
11. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
12. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space.
Tani M; Ito M; Igarashi Y
Cell Signal; 2007 Feb; 19(2):229-37. PubMed ID: 16963225
[TBL] [Abstract][Full Text] [Related]
13. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
14. Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism.
Huang C; Su L; Chen Y; Wu S; Sun R; Xu Q; Qiu X; Yang C; Kong X; Qin H; Zhao X; Jiang X; Wang K; Zhu Y; Wong PP
Pharmacol Res; 2023 Jan; 187():106558. PubMed ID: 36410675
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane.
Canals D; Jenkins RW; Roddy P; Hernández-Corbacho MJ; Obeid LM; Hannun YA
J Biol Chem; 2010 Oct; 285(42):32476-85. PubMed ID: 20679347
[TBL] [Abstract][Full Text] [Related]
16. Acid Ceramidase in Melanoma: EXPRESSION, LOCALIZATION, AND EFFECTS OF PHARMACOLOGICAL INHIBITION.
Realini N; Palese F; Pizzirani D; Pontis S; Basit A; Bach A; Ganesan A; Piomelli D
J Biol Chem; 2016 Jan; 291(5):2422-34. PubMed ID: 26553872
[TBL] [Abstract][Full Text] [Related]
17. Cancer treatment strategies targeting sphingolipid metabolism.
Oskouian B; Saba JD
Adv Exp Med Biol; 2010; 688():185-205. PubMed ID: 20919655
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeting of acid ceramidase: implications to cancer therapy.
Zeidan YH; Jenkins RW; Korman JB; Liu X; Obeid LM; Norris JS; Hannun YA
Curr Drug Targets; 2008 Aug; 9(8):653-61. PubMed ID: 18691012
[TBL] [Abstract][Full Text] [Related]
19. beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism.
Awad AB; Barta SL; Fink CS; Bradford PG
Mol Nutr Food Res; 2008 Apr; 52(4):419-26. PubMed ID: 18338406
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
